Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Pacific Edge named Top Bioscience Company in 2014

Pacific Edge named Top Bioscience Company in 2014


Pacific Edge has been named NZBIO’s top bioscience company for 2014. Pacific Edge was specifically recognised for building the profile and credibility of biotechnology and biotechnology companies in New Zealand.

The announcement of the industry accolade this week is further recognition for the Dunedin based cancer diagnostic company and comes a few months after taking the Supreme Award at the NZ Innovation Council Awards.

Pacific Edge Chief Executive Office David Darling says the Company is delighted to receive the recognition for the advances being made to the clinical capability for the detection and management of cancers. The company’s Urine Sampling System is becoming a core element of the advances in clinical utility, which can be used by the patient in-home to take a sample.

“It is rare in the biotechnology sector to have a company with the capability and resources to go from discovery science all the way through clinical trials and product development to finally making a commercial product as Pacific Edge has done with Cxbladder – our molecular diagnostic test for bladder cancer.”

Cxbladder is a non-invasive test with the Company’s easy to use Urine Sampling System becoming a core element of the advances in clinical utility, which allows patients can use at home. The sample is analysed in one of Pacific Edge’s laboratories for the tell-tale molecular markers that will provide the urologist with information on the probability of the patient having bladder cancer, or not.

Cxbladder is now available commercially in the United States through the company’s own CLIA and CAP regulated laboratory in Hershey, Pennsylvania. In the later part of 2013 the company signed three large, preferred national provider networks. These provider networks provide patients access to healthcare services and technology by contracting with providers and payers on a national basis. These three agreements signed with FedMed, ACPN and Stratose give millions of Americans access to Cxbladder and its positive benefits as a quick, cost effective, non-invasive and highly accurate cancer detection test that is particularly appealing to US healthcare professionals, patients, and insurers.

The custom built, commercial laboratory for Pacific Edge’s US subsidiary PEDUSA was completed in September 2012 to process Cxbladder samples, was certified in 2013 by CLIA and more recently by CAP, to enable the laboratory to offer Cxbladder as a Laboratory Developed Test (LDT) to clinicians and physicians.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

What Winter? Temperature Records Set For June 20-22

The days around the winter soltice produced a number of notably warm tempertaures. More>>

Conservation Deal: New Kākāpō Recovery Partnership Welcomed

Conservation Minister Maggie Barry says the new kakapo recovery partnership between DOC and Meridian Energy is great news for efforts to save one of New Zealand’s most beloved birds. More>>

ALSO:

Tech Sector Report: Joyce Warns Asian Tech Investors View NZ As Hobbits And Food

Speaking in Wellington at the launch of a report showcasing the value of the technology sector to the New Zealand economy, Joyce said more had to be done to tell the country's technology stories overseas. More>>

ALSO:

Mediaglommeration: APN Gets OIO Approval For Demerger Plan

APN News & Media has received Overseas Investment Office approval for its plan to split out its NZME unit ahead of a potential merger with rival Fairfax Media's New Zealand operations. More>>

New Paper: Ninety-Day Trial Period Has No Impact On Firms' Hiring

The introduction of a 90-day trial period has had no impact on hiring by New Zealand companies although they are now in widespread use, according to researchers at Motu Economic and Public Policy Research. More>>

ALSO:

Corrections: Serco Exits Equity Stake, Remains As Operator

Serco has sold its equity stake in the company that holds the contract to design, build and run Wiri Prison in South Auckland but continues as sub-contractor to operate the facility. More>>

GDP: NZ Economy Grows Faster-Than-Forecast 0.7%

New Zealand's economy grew at a faster pace than expected in the first quarter of 2016 as construction expanded at the quickest rate in two years. The kiwi dollar jumped after the data was released. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news